Back to news

argenx Falls After Phase 3 Sjögren’s Study Is Stopped for Futility

Investivoq PriceTracker

argenx SE (ARGX) is down 13.8% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely driver is argenx’s decision to discontinue the Phase 3 UNITY study of subcutaneous efgartigimod in moderate-to-severe Sjögren’s disease after an interim review found the trial was unlikely to hit its main goal. For investors, that removes a potential label expansion opportunity for VYVGART in a large autoimmune indication, which appears to have outweighed other pipeline updates released the same day.

Details:

  • argenx said it will stop the Phase 3 UNITY trial in Sjögren’s disease after an Independent Data Monitoring Committee recommended halting the study for futility.
  • The company said the interim analysis indicated the study was unlikely to meet its primary endpoint, which was change in systemic disease activity at Week 48.
  • argenx also said no new safety signals were identified, suggesting the setback was tied to efficacy rather than an unexpected tolerability problem.
  • On the same day, argenx reported positive Phase 2 topline results for FB102 in celiac disease and said it plans to move that program into Phase 3, but that positive update was not enough to offset the Sjögren’s disappointment.

    • Sources:

    argenx, ClinicalTrials.gov, MarketScreener

    Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

    EARLY ACCESS
    Receive ARGX Data Alerts
    Real-time alerts on filings, insider trades, and market signals — before everyone else.
    Get Alerts →

    $ARGX Hedge Fund Activity

    We have seen 250 institutional investors add shares of $ARGX stock to their portfolio, and 205 decrease their positions in their most recent quarter.

    Here are some of the largest recent moves:

    • PRICE T ROWE ASSOCIATES INC /MD/ removed 696,908 shares (-20.6%) from their portfolio in Q2 2026, for an estimated $646,570,335
    • FMR LLC added 240,418 shares (+4.8%) to their portfolio in Q2 2026, for an estimated $223,052,607
    • BESSEMER GROUP INC added 203,528 shares (+316.8%) to their portfolio in Q2 2026, for an estimated $188,827,172
    • INVESCO LTD. removed 150,707 shares (-25.3%) from their portfolio in Q2 2026, for an estimated $139,821,433
    • BARCLAYS PLC added 128,927 shares (+2344.1%) to their portfolio in Q2 2026, for an estimated $119,614,602
    • FIERA CAPITAL CORP removed 126,775 shares (-58.4%) from their portfolio in Q2 2026, for an estimated $117,618,041
    • WELLINGTON MANAGEMENT GROUP LLP removed 90,909 shares (-8.9%) from their portfolio in Q2 2026, for an estimated $84,342,642

    To track hedge funds' stock portfolios, check out Investivoq's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Investivoq API 13F endpoint.

    $ARGX Price Targets

    Multiple analysts have issued price targets for $ARGX recently. We have seen 8 analysts offer price targets for $ARGX in the last 6 months, with a median target of $1073.5.

    Here are some recent targets:

    • Luca Issi from RBC Capital set a target price of $945.0 on 07/07/2026
    • Tazeen Ahmad from B of A Securities set a target price of $1088.0 on 07/02/2026
    • Douglas Tsao from HC Wainwright & Co. set a target price of $940.0 on 06/25/2026
    • Matthew Harrison from Morgan Stanley set a target price of $1180.0 on 06/24/2026
    • David Nierengarten from Wedbush set a target price of $1000.0 on 06/11/2026
    • Derek Archila from Wells Fargo set a target price of $1291.0 on 06/01/2026
    • Gavin Clark-Gartner from Evercore ISI Group set a target price of $1059.0 on 05/15/2026

    This article is not financial advice. See Investivoq's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.